Psilocybin for PTSD with or without Psychotherapy: A Pilot study of safety and efficacy outcomes – The first characterization of nightmare burden in PTSD following psilocybin administration
25 mg first session; option to increase to 35 mg for second session, otherwise 25 mg
Duration
8 hours of preparatory meetings over approximately 2 weeks, two psilocybin sessions separated by approximately 2 weeks, seven post-session integration visits, and follow-up assessments
The abstract reports the design and dosing schedule of a nightmare-focused analysis within an open-label psilocybin pilot trial but does not present any nightmare-related results or conclusions.
Abstract
This nightmare-focused study was conducted based on data collected in an open-label, controlled treatment pilot trial conducted at the Johns Hopkins Center for Psychedelic and Consciousness Research (CPCR) under an approved protocol (IRB00407008; NCT06407635). Participants completed screening, baseline assessment, four preparatory sessions, two psilocybin dosing sessions, seven post-session integration visits, and follow-up assessments. The intervention consisted of 8 hours of preparatory meetings (over approximately 2 weeks), followed by 2 psilocybin sessions separated by approximately 2 weeks. Participants received 25 mg in the first session. The participant was given the option of increasing to 35 mg for the second dose. Otherwise, the dose on the first and second session was 25 mg. Eighteen participants completed nightmare-related assessments.
In the evidence
This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.
Reports the design and dosing schedule (25 mg, optional 35 mg second session) of a nightmare-focused analysis but presents no nightmare-related results.
Synthesized
Comparable studies
Other non-randomized and open-label trials on
psilocybin for PTSD, most cited first.